The McSwiggen patent estate broadly describes chemical modifications of RNAi therapeutics that the company believes are critical for achieving ‘drug-like’ properties in siRNA, the molecules that mediate RNAi.
The company has designed GENASSIST to make genome editing accessible for everyone. Horizon offers not just plasmids for CRISPR gene editing, but also custom guide RNA design and
Cedarburg, whose capabilities both augment and complement those of AMRI, is a contract developer and manufacturer of technically complex active pharmaceutical ingredients (API’s) for both generic and branded
The FDA action date (PDUFA date) for Fibrocaps is 31 January 2015. In August 2013, The Medicines Company announced that the Phase III trial, FINISH-3, which studied a
Otezla is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). Otezla was approved by the FDA on 21 March 2014, and is
Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments. Eisai will partner with Abela Frères to market eribulin in
Emapticap pegol is a Spiegelmer that binds and neutralizes CCL2/MCP-1 (C-C Chemokine Ligand / Monocyte Chemoattractant Protein-1), a pro-inflammatory chemokine that plays an important role in diabetic kidney
The formation of Spectromics is the result of three years of research by Professor Roy Goodacre of the Institute of Biotechnology and School of Chemistry at The University
The study is entitled ‘A Phase I, Open Label, Dose Escalation Study of Immunoconjugate L-DOS47 in Combination with Standard Doublet Therapy of Pemetrexed/Carboplatin in Patients with Stage IV
EVZIO is the first and only naloxone auto-injector intended to be available for immediate administration by family members or caregivers for suspected opioid overdose in settings where opioids
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.